Monte Rosa Therapeutics, Inc. (GLUE) – What Are Brokerages Thinking About This Stock?

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been given a consensus rating of “Moderate Buy” by the twelve ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $26.44.

Several research analysts recently weighed in on GLUE shares. Jefferies Financial Group reissued a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Zacks Research raised Monte Rosa Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Weiss Ratings downgraded Monte Rosa Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Guggenheim reiterated a “buy” rating and issued a $28.00 price target on shares of Monte Rosa Therapeutics in a research report on Tuesday, August 25th. Finally, Wedbush reaffirmed an “outperform” rating and set a $27.00 price target on shares of Monte Rosa Therapeutics in a research note on Wednesday, September 9th.

Monte Rosa Therapeutics Stock Performance

Shares of Monte Rosa Therapeutics stock opened at $10.57 on Friday. Monte Rosa Therapeutics has a fifty-two week low of $9.68 and a fifty-two week high of $25.77. The company has a market capitalization of $901.73 million, a P/E ratio of -7.55 and a beta of 1.40. The company has a fifty day moving average of $11.70 and a 200 day moving average of $17.09.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, November 5th. The company reported $0.03 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.24. The company had revenue of $54.37 million during the quarter, compared to analysts’ expectations of $33.87 million. Monte Rosa Therapeutics had a negative return on equity of 43.31% and a negative net margin of 560.85%. Analysts forecast that Monte Rosa Therapeutics will post -1.13 EPS for the current year.

Hedge Funds Weigh In On Monte Rosa Therapeutics

A number of large investors have recently bought and sold shares of GLUE. AlphaCentric Advisors LLC raised its holdings in Monte Rosa Therapeutics by 112.0% during the third quarter. AlphaCentric Advisors LLC now owns 26,802 shares of the company’s stock worth $320,000 after purchasing an additional 14,157 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Monte Rosa Therapeutics during the third quarter worth about $52,000. Profund Advisors LLC grew its position in shares of Monte Rosa Therapeutics by 7.6% during the 3rd quarter. Profund Advisors LLC now owns 32,406 shares of the company’s stock worth $387,000 after purchasing an additional 2,295 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Monte Rosa Therapeutics by 14.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 17,166 shares of the company’s stock valued at $202,000 after purchasing an additional 2,121 shares during the last quarter. Finally, Sterling Capital Management LLC lifted its holdings in Monte Rosa Therapeutics by 842.3% during the third quarter. Sterling Capital Management LLC now owns 2,450 shares of the company’s stock worth $29,000 after acquiring an additional 2,190 shares during the period. Institutional investors and hedge funds own 79.96% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics, Inc is a clinical-stage biotechnology company focused on developing molecular glue degraders, a class of medicines designed to eliminate disease-causing proteins by directing them to the cell’s natural protein-degradation machinery. The company’s approach is intended to address targets that may be difficult to inhibit with conventional small-molecule drugs.

Monte Rosa uses its QuEEN platform to discover and optimize molecular glue degraders for diseases involving dysregulated immune responses and other biological pathways.